Glioma Treatment Global Market Report 2025

Glioma treatment involves interventions aimed at reducing symptoms, controlling and removing tumors, and mitigating long-term damage to the brain or spinal cord. These treatments are crucial for eliminating any remaining glioma cells post-surgery.

Glioma treatment encompasses two main types, low-grade and high-grade. Low-grade gliomas are tumors that develop in the brain and typically exhibit slow growth. Diseases such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others are addressed through various routes of administration, including oral and parenteral methods. These conditions can be treated with diverse surgeries, including radiation therapy, chemotherapy, targeted drug therapy, and others. The end users of glioma treatment include hospitals, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The glioma treatment market research report is one of a series of new reports from The Business Research Company that provides glioma treatment market statistics, including glioma treatment industry global market size, regional shares, competitors with a glioma treatment market share, detailed glioma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the glioma treatment industry. This glioma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glioma treatment market size has grown strongly in recent years. It will grow from $5.06 billion in 2024 to $5.37 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the risen incidence of gliomas, advancements in molecular understanding, evolution of standard therapies, clinical trials and research progress, and improved imaging and diagnostic techniques.

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $6.94 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized therapies and biomarker discovery, immunotherapeutic advancements, integration of targeted therapies, the emergence of novel therapeutic platforms, and collaborative research initiatives. Major trends in the forecast period include blood-brain barrier penetrating agents, liquid biopsy for monitoring, focus on the quality of life and supportive care, genetic and molecular subtyping, patient advocacy and involvement.

The forecast of 6.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. brain tumor management by inflating prices of lomustine and MRI-guided laser ablation systems developed in Germany and Canada, resulting in delayed interventions and higher neurosurgical expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated increase in the incidence of brain and CNS tumors is expected to drive the growth of the glioma treatment market. Brain and spinal cord tumors are abnormal masses in the brain or central nervous system. Glioma treatment is utilized in the management of brain and spinal cord cancer to eliminate any residual cancer cells or portions of the tumor post-surgery. For instance, as of August 2021, the American Cancer Society reported an estimated 83,570 cases, including 24,530 malignant tumors and 59,040 nonmalignant tumors, with 18,600 deaths from brain and other CNS cancers in the United States for the year 2021. Hence, the increasing incidence of brain and spinal cord tumors is a key driver for the growth of the glioma treatment market.

The rising demand for personalized medicine is projected to drive the growth of the glioma treatment market in the coming years. Personalized medicine involves a tailored healthcare approach that considers individual patient characteristics, such as genetics, environment, and lifestyle, to improve treatment effectiveness and outcomes. Several factors are fueling this demand, including advancements in genomics, increased patient empowerment, and enhanced treatment efficacy. Identifying biomarkers associated with gliomas is crucial for predicting treatment responses and outcomes, allowing for the development of personalized treatment plans that cater to the unique characteristics of each patient. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the growing demand for personalized medicine is a key driver of the glioma treatment market.

Product innovation is a significant trend gaining traction in the glioma treatment market. Leading companies in this sector are introducing new and innovative products to maintain their competitive edge. For example, in June 2024, Servier Pharmaceuticals, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval marks a notable milestone as it represents the first targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib is a dual inhibitor that targets mutations in isocitrate dehydrogenase (IDH) 1 and 2, which are frequently associated with gliomas. These mutations lead to the production of 2-hydroxyglutarate (2-HG), a metabolite that fosters tumor growth and survival. By inhibiting these enzymes, vorasidenib lowers 2-HG levels, potentially slowing the progression of the tumor.

Prominent companies in the glioma treatment market are concentrating on the introduction of advanced targeted therapy solutions, particularly combination medicines, to gain a competitive advantage. Combination medicines aim to offer a more effective and convenient treatment option for patients dealing with complex medical conditions such as glioma. For instance, in May 2023, Novartis AG, a Swiss pharmaceutical corporation, received approval from the U.S. Food and Drug Administration (FDA) for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients (at least one year old) with low-grade gliomas (LGGs) harboring a BRAF V600E mutation and requiring systemic therapy. This approval marks the first combination targeted medication endorsed for the treatment of BRAF V600E LGG in pediatric patients, offering a potential new standard of care therapy option. Pediatric LGG is the most prevalent type of pediatric brain cancer, with BRAF V600 mutations present in 15-25% of cases, associated with poor survival outcomes and less favorable responses to chemotherapy.

In February 2023, Kite, a global biopharmaceutical company based in the U.S., completed the acquisition of Tmunity Therapeutics for an undisclosed amount. This strategic move enhances Kite's internal capabilities in cell therapy research by incorporating additional pipeline assets. The acquisition provides access to pre-clinical and clinical programs, including an 'armored' CAR T technology platform, with the potential to enhance the anti-tumor activity of various CAR-Ts. Tmunity Therapeutics Inc., the acquired company, focuses on developing innovative products for the treatment of diffuse intrinsic pontine glioma.

Major companies operating in the glioma treatment market include Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

North America was the largest region in the glioma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glioma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glioma treatment market includes revenues earned by entities by cerebral spinal fluid diversion, internal radiation therapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glioma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glioma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glioma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glioma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Low-Grade; High-Grade
• 2) By Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Other Diseases
• 3) By Route Of Administration: Oral; Parenteral; Other Routes
• 4) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Drug Therapy; Other Treatments
• 5) By End-User: Hospitals; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Low-Grade: Astrocytoma; Oligodendroglioma; Mixed Glioma
• 2) By High-Grade: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma
• Companies Mentioned: Merck & Co Inc.; Amgen Inc.; F Hoffmann-La Roche AG; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals LLC; Amneal Pharmaceuticals Inc.; Karyopharm Therapeutics Inc.; Bristol-Myers Squibb Co.; Rigel Pharmaceuticals Inc.; Sumitomo Dainippon Pharma Oncology Inc.; Emcure Pharmaceuticals Ltd.; Novartis AG; AstraZeneca plc; Eli Lilly and Company; Sanofi S.A.; Johnson & Johnson; AbbVie Inc.; Takeda Pharmaceutical Company Limited; GlaxoSmithKline plc; Bayer AG; Gilead Sciences Inc.; Ipsen Pharma; Eisai Co. Ltd.; Genentech Inc.; Iovance Biotherapeutics Inc.; Agios Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.